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Summary  
European countries have been affected by health but also economic and social challenges during the 
major crisis caused by the coronavirus disease (COVID-19) pandemic. The European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) reacted quickly to the crisis by assessing, with the 
support of the Reitox network, the implications of COVID-19 for people who use drugs and for drug 
services. The Reitox network is composed of 29 national drug observatories (i.e. those of the 27 EU 
Member States, Norway and Turkey), which also serve as the national focal points (NFPs) to the 
EMCDDA and the European Commission. Under Member States’ responsibility and EMCDDA 
guidance, Reitox NFPs have been responsible for (1) collecting, harmonising and analysing national 
information according to EMCDDA standards and providing this information to the EMCDDA; (2) 
monitoring and analysing national scientific, legal and policy developments; (3) coordinating and 
animating national drug information network(s); (4) participating actively in the EMCDDA’s tasking 
processes; (5) ensuring the production and dissemination of NFP outputs nationally; (6) cooperating 
in improving existing EMCDDA working areas; (7) cooperating in the conceptualisation of new key 
indicators and core datasets; (8) language checking and proofreading of EMCDDA products and 
publications; and (9) disseminating at the national level EMCDDA and Reitox outputs. 
Most of the Reitox NFPs are under the authority of their ministry of health or national public health 
institute and have been closely associated with COVID-19 crisis management, not only in relation to 
drug-related issues, but also as regards the wider scope of public health. Despite the fact that the 
NFPs had to adjust their work to the emerging restrictions, they led or contributed to a wide range of 
activities, such as carrying out risk assessments and new surveys, monitoring possible COVID-19 
outbreaks among risk groups, providing guidance to stakeholders and supporting (new) drug-related 
services. 
People who use drugs are recognised as a vulnerable group and, during the COVID-19 pandemic, 
this group has been at risk of becoming seriously ill if infected because of their health status. 
Therefore, it is essential to communicate appropriate and timely advice to this group to reduce the risk 
of infection. In this context, the NFPs contributed to several of the EMCDDA COVID-19 special 
activities, such as the surveys for the Trendspotter briefings on the impact of COVID-19 on service 
provision and help-seeking behaviour among people who use drugs and on patterns of drug use and 
drug-related harms. They also contributed to the translation and dissemination of other ad hoc 
EMCDDA publications, such as reports on COVID-19 and EU drug markets, drug supply via darknet 
markets, the implications for people who use drugs, and more. 
The NFPs performed many extra activities that were outside their mandate as NFPs to the EMCDDA 
by providing expertise to different stakeholders and policymakers. They were involved in drafting, 
creating and providing national guidelines, disseminating information to drug users and the staff of 
drug services, and providing new services. 
The NFPs came across many challenges related to their working conditions, such as a reduction in 
staff, a shift of human resources to other teams involved in monitoring the pandemic and the transition 
to teleworking. Most of the tasks undertaken by NFPs could be conducted remotely and, despite 
some difficulties, such as the lack of availability of technological means, the NFPs adapted rapidly 
and effectively to the new conditions and did not experience an interruption to their activities. 
However, given that health-related matters associated with COVID-19 became a public health priority, 
some of the NFPs’ routine data collection, as well some surveys, were postponed from spring to 
autumn and a few even to 2021. Many countries might also be confronted with data challenges in the 
coming years, as it is not yet clear how much the COVID-19 pandemic has affected data collection 
and data reporting among some drug-related service providers. 
Despite these challenges, there was no major disruption to the work of the NFPs owing to their 
significant and long-running experience with systemic drug-related monitoring and reporting activities. 
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Despite the sudden change in priorities, the sustainability of the NFPs was not at all at stake. Reitox 
NFPs are used to risk management and are experienced in crisis communication, which were 
highlighted as important assets of the Reitox network during the COVID-19 pandemic. Moreover, the 
NFPs demonstrated a significant ability to adapt and shift their working mode, despite staff 
relocations, as already mentioned. 
During the lockdown in spring, the NFPs increased their national collaboration with different 
stakeholders, ensuring that more efficient data collection could be carried out during this time of crisis. 
The NFPs have organised online meetings and webinars at the national and international levels, 
involving even more local decision-makers than usual, to allow information flow and communication 
back and forth. 
The existing knowledge within the Reitox network and the opportunity that the network provided to 
easily exchange experiences and best practices were key during the crisis. With rapid changes in 
drug use patterns and other challenges, the network provided real added value for the NFPs and their 
national stakeholders, bringing back the added value at the EU level to the national level. As 
highlighted in the Reitox Development Framework (EMCDDA, 2017), to achieve a powerful collective 
impact, the strengthening of horizontal cooperation between NFPs and the exchange of best practices 
in monitoring the drug situation are key. 
The NFPs played a key role in acting as coordinators in this time of crisis, when human resources 
were scarce at different levels. It was critical that a coherent monitoring approach be maintained, that 
the possible overlapping of national or local surveys be limited and that the production of appropriate 
and timely responses be guaranteed. The leadership of the NFPs was essential and they 
demonstrated that they can achieve a lot, with simplified procedures, under extreme time pressure 
and sometimes with very scarce resources. 
In these times, the Reitox network has shown that it fully shares and contributes to the EMCDDA’s 
vision of a healthier and more secure Europe through better informed drug policies and actions, with 
each NFP contributing to making its own country healthier and more secure through the data it 
collects and analyses, and the information it provides. 
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Introduction 
The major public health crisis caused by the rapid spread of coronavirus disease (COVID-19) has 
affected European societies. Governments have had to take public health decisions, promoting social 
distancing, restricting movements and even imposing lockdowns, as well as socioeconomic 
measures. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) reacted rapidly 
to the crisis by assessing and publishing, in March 2020, an update on the implications of COVID-19 
for people who use drugs and for drug service providers (EMCDDA, 2020a). 
Since the beginning of the coronavirus pandemic, the European Centre for Disease Prevention and 
Control (ECDC) has been collating the number of COVID-19 cases and deaths, based on reports 
from health authorities (ECDC, 2020). The ECDC receives data mainly through the Early Warning and 
Response System (EWRS), the European Surveillance System (TESSy) and the World Health 
Organization (WHO). In the EU Member States, ministries of health, public health institutes and other 
national authorities are at the front line of the crisis. 
Reitox is the European information network on drugs and drug addiction and it contributes to the 
EMCDDA’s mission, that is, to create a healthier and more secure Europe through better-informed 
drug policies and actions. The Reitox national focal points (NFPs) are national bodies designated by 
each EMCDDA participating country (the EU Member States, Norway and Turkey) to collect, analyse 
and report data at the national level on drugs and drug addiction to the EMCDDA. Each NFP is the 
primary source of national information at the EU level. Two thirds of NFPs are located in, or are 
closely linked to, their ministry of health or national public health institute (Figure 1). Given their 
institutional affiliation, most NFPs have been closely involved in COVID-19 crisis management at the 
national level since the beginning of the pandemic, not only as regards drug-related issues, but also in 
relation to general public health issues. NFPs have led, or contributed to, a wide range of activities 
such as risk assessment, monitoring the COVID-19 epidemic among vulnerable groups, providing 
guidance to stakeholders, carrying out surveys on addictive behaviours, and providing funding to 
reinforce services or create new ones. 
 
Figure 1 
NFPs’ parent institutions 
 
Source: Reitox national focal points documentation 2020, internal. 
 
COVID-19 can cause a wide range of harms for people who use drugs. Pre-existing health problems 
and particular drug use behaviours can increase the risk of becoming seriously ill if people become 
infected (EMCDDA, 2020b). People who use drugs are an especially vulnerable group and they need 
to be particularly aware of the relevant advice to reduce their risk of infection. 
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The NFPs collaborated in many of the EMCDDA’s special COVID-19 activities. For instance, they 
contributed to the gathering of information, resulting in the following publications: in May 2020, a 
Trendspotter briefing entitled Impact of COVID-19 on Drug Services and Help-seeking in Europe 
(EMCDDA, 2020c), and, in June 2020, a Trendspotter briefing entitled Impact of COVID-19 on 
Patterns of Drug Use and Drug-related Harms in Europe (EMCDDA, 2020b). The NFPs also 
contributed to the translation and dissemination of ad hoc publications, such as EU Drug Markets: 
Impact of COVID-19 (EMCDDA and Europol, 2020) and a special report entitled COVID-19 and 
Drugs: Drug Supply via Darknet Markets (EMCDDA, 2020d). 
The NFPs compiled the list of activities that they performed at the national level to address the 
COVID-19 health crisis, between May and July 2020, for the purpose of this report. 
This report highlights the immediate responses taken by NFPs and describes the challenges met by 
the organisations and the strategies produced to overcome these challenges. In the first section, the 
focus is on different monitoring activities during the COVID-19 health crisis. The report also describes 
the responses of the NFPs, such as the provision of scientific expertise for guidelines, reports and 
policy recommendations, but also the dissemination of COVID-19-related information to their various 
audiences and the provision of new services. The report also draws attention to the impact of COVID-
19 on the NFPs as organisations, namely its consequences on working conditions and on NFPs’ 
monitoring activities. Finally, the last section focuses on the lessons learned so far. 
Responses of the national focal points to the COVID-19 
crisis 
Monitoring activities 
Despite the challenges created by the pandemic, NFPs continued to actively monitor the drug 
situation. The NFPs have strong national monitoring systems in place and use the EMCDDA’s 
standardised indicator protocols for regular monitoring. In spring 2020, the EMCDDA rapidly 
developed several specific surveys for the COVID-19 context, to which the NFPs contributed. These 
were the Mini European Web Survey on Drugs (Mini-EWSD), a series of trendspotter surveys, an EU 
drug market analysis, a prison survey, a European Syringe Collection and Analysis Project Enterprise 
(Escape) study and a Trans European Drug Information (TEDI) study. Some countries also 
participated in different surveys that were coordinated by other international organisations and EU 
agencies. 
During this period, some countries launched special tools designed to monitor the situation during the 
COVID-19 health emergency. Countries developed new surveys and questionnaires and conducted 
new analyses based on the routine data from their monitoring systems. A few countries initiated 
wastewater analysis or began COVID-19 case tracking among drug users. 
Table 1, in the annex, includes the list of national studies and projects, with links to documents where 
available. 
Participation in EMCDDA projects 
Mini-EWSD: the impact of COVID-19 on patterns of drug use, harms and drug services in the 
European Union 
The EMCDDA conducted a special COVID-19 round of the European Web Survey (the Mini-EWDS) 
(EMCDDA, 2020e) to assess the impact of COVID-19 on people who use drugs. The survey gathered 
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information on patterns of drug use, access to health services, drug markets and the impact of 
COVID-19-related restrictions. 
Most countries participated in the survey, which was translated into 21 languages and made available 
between 8 and 25 May 2020. The role of the NFPs was to translate, disseminate and promote the 
survey among their stakeholders and networks. In addition, some of them published or are planning to 
publish the national figures and analysis in a chapter of a COVID-19 report or in other specific reports 
(i.e. Ireland, Greece, Spain (DGPNSD OEDA, 2020a), Latvia, Lithuania (1), Luxembourg and 
Slovenia). Around 10 600 respondents completed the online questionnaire (with around 30 questions) 
in one of the languages available. This contributed to the production of a comprehensive, realistic and 
timely picture of drug use in Europe and to the overall analysis of the situation and of the changes 
associated with the COVID-19 pandemic and its consequences (EMCDDA, 2020b). 
Trendspotter studies on the effects and implications of the COVID-19 outbreak on drug 
services and patterns of drug use 
The series of EMCDDA trendspotter studies investigated the effects and implications of the first wave 
of the COVID-19 outbreak on drug services and help-seeking in Europe (May 2020; EMCDDA, 
2020c), and the impact on patterns of drug use and drug-related harms in Europe among people who 
use drugs (June 2020; EMCDDA, 2020b). The series used a mixed-method approach to investigate 
the situation. The trendspotter methodology is based on the triangulation of a range of rapid 
investigative approaches and data collection from multiple quantitative and qualitative sources with a 
systematic analysis incorporating the use of expert opinion (EMCDDA, 2018a). The methodology 
used in the COVID-19 briefings had been adapted to suit online investigation, considering the national 
emergency restrictions. A literature review was performed, online expert surveys were organised, the 
Mini-EWSD was launched (see previous paragraph) and various virtual facilitated groups were 
created made up of European drug professionals, researchers and representatives. 
In April 2020, an initial online survey was sent to the Reitox network of NFPs. One of the focus groups 
organised in the trendspotter study involved three NFPs, namely from Belgium, Czechia and France. 
A number of experts recommended by the NFPs participated in other focus groups. Many NFPs 
adapted the EMCDDA questionnaire and sent it to their national institutions, authorities, experts and 
drug-related services to provide the most reliable answers to the survey. 
The Austrian NFP published the national results of the questionnaire and shared them with all of its 
provincial networks (Horváth et al., 2020); several other NFPs also translated the trendspotter 
publication into their national languages and disseminated the results in this way. 
This exercise fostered collaboration between different organisations; for example, the Norwegian 
NFP completed the EMCDDA questionnaire in collaboration with the Norwegian Directorate of Health 
and KORUS Oslo, which have been implementing a weekly survey at municipal level since the start of 
the lockdown. Moreover, the completion of the questionnaire was informed by the efforts of the 
Norwegian Centre for Addiction Research (SERAF), which has been focusing on COVID-19 and the 
treatment of substance use disorders. 
The Polish NFP expanded on the trendspotter survey and undertook a rapid assessment on the 
impact of COVID-19 on drug services, drug users and the drug market. The results were published in 
English (Malczewski et al., 2020) and were also presented in a series of webinars, organised in June 
and October as a part of a national conference held in Warsaw. Moreover, the results of the survey 
were published in four Polish scientific journals. 
 
(1) Results were presented to the media on 22 July 2020 (Narkotikų, tabako ir alkoholio kontrolės departamentas, 
2020). 
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Like its Polish counterpart, the Hungarian NFP expanded on the trendspotter survey and created a 
national questionnaire for drug service providers about drug use, health and social risks, and access 
to treatment and harm reduction services. It also included questions on changes in drug prices and 
availability. Following the COVID-19 outbreak, the Hungarian social system had to face more and 
different challenges, handle more needs and develop complex responses to food provision, shelter, 
daily care, asylums in lockdown, etc., while the healthcare system struggled to continue adequately 
providing care. Referral and admission of new cases in many units was stopped (psychiatry, 
addiction, HIV/hepatitis C virus (HCV) treatment, etc.) to avoid overload and nosocomial infections 
due to the pandemic. The NFP produced a detailed report of the results of the questionnaire and a 
briefing, both of which are currently under assessment by decision-makers and have not yet been 
published. 
Several other NFPs conducted ad hoc monitoring activities, which also contributed to the analysis of 
the state of drug services, such as a rapid assessment among treatment centres in Belgium to 
assess the impact of the pandemic on this specialised sector and on drug users. The results indicated 
that there had been changes in the services offered, gave an insight into the demands of the service 
users, those receiving opioid substitution treatment and COVID-19 patients among the drug users, 
and highlighted the specific requirements of the services. The results were shared with the authorities 
and the drug treatment services (in French and Dutch). In France, the French Monitoring Centre for 
Drugs and Drug Addiction (OFDT) undertook qualitative monitoring based on the feedback from its 
TREND scheme and network in seven large cities (Bordeaux, Lille, Lyon, Marseille, Metz, Paris and 
Rennes). The results of this rapid assessment among harm reduction facilities were published online 
in French and English (Gérome and Gandilhon, 2020a, 2020b). In Slovenia, the NFP also 
summarised the results of a rapid assessment of the situation in a report published in Slovenian on 
the website of the National Institute of Public Health (NIJZ) entitled, in English, The impact of the 
COVID-19 pandemic on treatment and provision services for drug users and on the drug market in 
Slovenia (Drev, 2020). 
In Cyprus, an assessment of changes in treatment demand and treatment provision was performed; 
the results, which provided information on the mode of treatment provision and working hours of 
services, were published on the website of the Cyprus National Addictions Authority. The Irish NFP 
undertook a rapid assessment of the impact of COVID-19 through the Department of Health and 
Social Care. During May and June, staff in the National Drug Treatment Reporting System, based at 
the Irish NFP, telephoned all of the treatment services that were submitting treatment demand data to 
ascertain the impact of the pandemic on service provision. In Romania, in addition to compiling 
answers to the trendspotter questionnaire, the NFP also processed the available national treatment 
demand data (based on the treatment demand indicator) from January to March for a special 
analysis. In addition, in Italy, an ad hoc monitoring activity was carried out focusing on changes in 
treatment requests and the provision of treatment and involving a group of social- and healthcare staff 
of treatment centres. 
Furthermore, in Finland, the NFP performed a survey among drug service providers on the changes 
in service provision and demand. The NFP has conducted this survey every 5 weeks since the 
beginning of the epidemic, collecting data for the Ministry of Social Affairs and Health, which is 
responsible for service monitoring during the crisis. As a result, a blog was published and a 
publication will possibly be drafted. 
Drug market survey 
A joint publication of the EMCDDA and Europol analyses the effect that the COVID-19 pandemic has 
had on EU drug markets, for the main drug types (cannabis, heroin, cocaine, amphetamines and new 
psychoactive substances), including on demand, production, trafficking and availability (EMCDDA and 
Europol, 2020). For this publication, the EMCDDA conducted a targeted online survey in April 2020. 
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The Reitox network supported the data collection by strengthening collaboration with supply reference 
experts working in different services such as in the police. 
Prisons: cooperation on monitoring and reporting 
In settings in which people are gathered in enclosed environments such as in prisons, there is a 
heightened risk of person-to-person and droplet transmission of pathogens such as coronavirus. 
People in prisons also have a greater underlying burden of disease and worse health conditions than 
the general population (WHO, 2020a, 2020b). 
The EMCDDA collects data on prison settings to closely monitor this population. Fifteen countries 
have ensured the participation of prison experts in this survey up to now. 
In Luxembourg, the NFP ran an adapted version of the European questionnaire on drug use among 
prisoners, including several COVID-19-related questions, until the end of August 2020 in their national 
closed prisons among their complete inmate populations. Moreover, the Hungarian NFP conducted a 
national prison facility survey in September, which included COVID-19-related issues. The results of 
this study are expected to be available in the coming months. 
EU research projects 
Other international surveys and ad hoc studies were conducted in which NFPs played an active role 
in the drafting, piloting and creation, translation, review and dissemination of the surveys and data 
collection. 
For instance, the French NFP is piloting the Escape project (EMCDDA, 2019). An analysis of the 
substances injected using syringes during the lockdown period was done in Czechia with the 
participation of the Czech NFP. The Lithuanian, Latvian and Finnish NFPs are also collaborating in 
the project jointly with other partners from other countries. 
The TEDI (EMCDDA, undated) survey in Luxembourg fostered collaboration between partners of 
harm reduction, health education and drug checking services on the implementation of a survey on 
the impact of COVID-19 on recreational drug user habits. The NFP participated in testing the pilot, 
promoting the survey at the national level and reviewing the report. 
In addition to data collection for the EMCDDA, several NFPs have also completed the United Nations 
Office on Drugs and Crime (UNODC) special survey on a global initiative to improve knowledge on 
COVID-19’s impact on crime and drugs in June 2020. 
Ad hoc national studies 
In addition to data collection for the EMCDDA, and their usual monitoring activities as part of their 
mandates, NFPs also performed specific national studies or contributed to surveys initiated by other 
partners during spring 2020. One of the four strategic objectives of the Reitox Development 
Framework, a document that defines the main priorities of the Reitox network in fulfilling its roles and 
functions in the future, is to strengthen the role of the NFPs in supporting decision-making and action 
at the national level (EMCDDA, 2018b). This national work may also support horizontal cooperation 
between NFPs by giving them an opportunity to exchange best practices, to increase collaboration 
with each other and to support each other in having a powerful collective impact. In addition, it helps 
to increase the external visibility of the Reitox network as a whole by developing new products. 
Focus on services 
In Luxembourg, the NFP published, in collaboration with the National Statistics Institute (STATEC 
Luxembourg) and the national drug coordinator, a so-called ‘Flash COVID-19’ report on the impact of 
COVID-19 on drug users and national drug treatment and harm reduction service providers. It is a six-
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page factsheet/report. Another study has been conducted by the Luxembourg NFP in collaboration 
with the national drug coordinator and directors of drug treatment and harm reduction services, 
focusing on the evaluation of low-threshold services and their newly implemented low-threshold opioid 
substitution treatment offer. The study aims to assess the impact of COVID-19 and the national 
measures implemented on high-risk drug use clients attending national harm reduction and 
supervised drug consumption facilities. A short written questionnaire was distributed to participants 
between July and September 2020. Results should published by the end of 2020. 
In Lithuania, between March and May 2020, the NFP monitored alcohol and drug-related non-fatal 
overdoses by comparing 2019 data with the situation during the quarantine period and also compared 
changes in treatment demands (NTAKD, 2020a). 
The Greek NFP is assisting the national coordinator in the creation and dissemination of a 
questionnaire targeting drug professionals, focusing on their experience during the COVID-19 health 
emergency. The data collection is still ongoing. 
In Estonia, the NFP is very closely monitoring the effects of COVID-19 by collecting data from harm 
reduction services, treatment centres and other services. 
In March 2020, the Dutch NFP conducted an initial rapid assessment of the impact of the COVID-19 
measures on harm reduction facilities and their target groups. This rapid assessment was then 
repeated twice (in April and June). The study was done in collaboration with Mainline (a harm 
reduction service provider) and MDHG (a medical social service for drug users) (Van der Gouwe et 
al., 2020). The results were discussed with the Ministry of Health, and best practices were distributed 
to stakeholders in various ways. In October 2020, a fourth rapid assessment was conducted. 
In Czechia, the NFP has been actively monitoring the changes in treatment and harm reduction 
provision and has issued and published two rapid assessment reports (National Monitoring Centre for 
Drugs and Addiction, 2020a,b); a third rapid assessment report is in preparation. The rapid 
assessment reports aimed to inform national stakeholders of the impact of COVID-19 on the drug 
scene and on drug-related services. They were presented and endorsed in a session of the 
Government Council for Drug Policy Coordination on 25 June 2020. In addition, the Czech NFP 
monitored the interventions carried out by addiction services providers through an online facility 
survey, with COVID-19-related questions added to the routine questions. 
Focus on web surveys 
A new study on the impact of COVID-19 on addictive behaviours was conducted in Portugal. The 
Portuguese NFP launched three online surveys: the first related to alcohol and medication use, the 
second to the use of the internet and video games, and the third to the use of cannabis. The results of 
the surveys are available on the website of the General Directorate for Intervention on Addictive 
Behaviours and Dependencies (SICAD) and were disseminated through social networks. 
In the Netherlands, there are several national studies under way. The first survey investigated if 
cannabis users in the country changed their consumption patterns after the introduction of the 
coronavirus measures in mid-March and, if so, the reasons for change. A total of 1 563 participants 
were included in this study (Vercoulen et al., 2020). The (preliminary) findings received a lot of media 
attention, as these findings showed that 4 in 10 cannabis users increased their cannabis use as a 
result of the pandemic, mainly because of boredom, but stress and loneliness also played a role. In 
addition, the National Big Nightlife Survey 2020 was adapted to include COVID-19-related questions 
in the survey. The data collection phase lasted until the end of May (Van Miltenburg et al., 2020). The 
survey focused on the consequences of the measures in the first period of the lockdown in terms of 
the use of drugs, alcohol and tobacco among partygoers and young adults. The survey was repeated 
in September/October 2020. Moreover, in the Netherlands, the monitoring of internet and online apps 
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was intensified, such as the monitoring of users’ forums and Telegram Messenger, to investigate the 
effects of the crisis on drug markets. 
In Belgium, the NFP is undertaking a national web survey to monitor the impact of the COVID-19 
crisis on drug users by evaluating both drug-related and health-related issues relevant to health 
professionals, prevention services and decision-makers. The objective of the study is to support 
decision-making and professionals during the current pandemic and to determine its long- and 
medium-term consequences. Consequently, this web survey is being conducted in several waves and 
is still ongoing. The results of the first two waves of the study have been published in French and 
Dutch (Sciensano, 2020a, 2020b). 
In Italy, the NFP supported an online survey of a sample of Italian students. The survey aimed to 
evaluate changes in drug use during the lockdown, and it was conducted by the Institute of Clinical 
Physiology of the National Research Council of Italy. 
The Spanish NFP actively participated in monitoring the situation in Spain through several new 
studies. In July 2020, the NFP published a report on the impact of COVID-19 on the use of 
psychoactive substances and other addictions (DGPNSD OEDA, 2020b). The report combines 
multiple information sources, including regular drug-related monitoring databases (based on the 
treatment demand indicator, the drug-related death indicator and the drug-related emergencies 
indicator), the results of the Spanish Mini-EWDS on COVID-19, a web survey on betting, video games 
and gaming, and other studies on tobacco use and confinement, COVID-19 and cannabis, and 
alcohol, benzodiazepine and opioid use. 
In Czechia, the NFP carried out a national survey on substance use. This online survey, which is 
conducted every 4 years, was adapted and included a special module on the changes in substance 
use and addictive behaviours, such as gaming, gambling and social media use, during the COVID-19 
health emergency. 
The French NFP published a report on the impact of COVID-19 on the use of psychoactive 
substances, which also integrates the results of an online survey on cannabis use performed during 
July and August (OFDT, 2020). 
Focus on seroprevalence studies 
The Polish NFP and the National Institute of Public Health are planning to launch a new study 
entitled ‘Health conditions of people receiving injections in the field of infectious diseases — 
seroprevalence study on HIV, HCV, SARS-CoV-2 and bacteria Treponema pallidum’. 
The Hungarian NFP is also conducting a bio-behavioural survey on HIV/HCV and COVID-19 among 
high-risk drug users (including people who inject drugs) in Budapest. Biological samples are tested for 
HIV/HCV, with participants completing a questionnaire that includes COVID-19-related questions. The 
NFP also conducted interviews among key informants about changes in the drug market and seizures 
of drugs by authorities, emergency care and acute intoxications, and forensic medicine. 
The Czech NFP and the national drug policy coordination office also conducted a new 
serobehavioural study entitled ‘ADI-COVID-19’. The study aimed to determine the seroprevalence of 
coronavirus (SARS-CoV-2) infection and to identify suspected cases of infection among clients and 
staff of addiction rehabilitation programmes. The study included rapid testing and a questionnaire 
distributed among clients and workers of drug services. Tests and personal protective equipment 
were provided to the services. 
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Focus on wastewater studies 
For about a decade, wastewater analysis has been used to monitor and estimate illicit drug 
consumption at the city level. In 2019, 23 countries in Europe (68 cities) participated in the latest 
wastewater monitoring project (EMCDDA, 2020f). 
In 2020, during the COVID-19 crisis, in three countries — Cyprus, Portugal and Slovakia — the NFPs 
supported the implementation of additional wastewater studies to identify drug use (EMCDDA, 2020f). 
In Cyprus, there were two collections of wastewater, namely during and after the lockdown. In 
Slovakia, the ongoing wastewater analysis focuses mainly on the following substances: 
methamphetamine, fentanyl, ketamine, amphetamine, cocaine, benzoylecgonine, MDMA, THC-
COOH, tramadol, methadone, mephedrone and heroin. Portugal also coordinated with the waste 
water based expert on the collection of samples in three different time periods to assess the possible 
impact of the COVID-19 measures on drug use. 
Focus on COVID-19 case tracking 
One of the new monitoring activities that has been embedded into some of the NFPs’ practices is 
COVID-19 case tracking among drug users. For instance, the Luxembourg NFP, in collaboration with 
the National Laboratory on Health, collects data on COVID-19 infections among cases of drug-related 
deaths. This is an ongoing activity, with (co-)infections of COVID-19 having been assessed since May 
2020 among drug-related death cases in the population in Luxembourg. Similarly, in Greece, with the 
use of data from agencies, the number of drug users infected by or deceased as a result of COVID-19 
is being monitored. In Italy, a working group has published a report on infection prevention and 
control for COVID-19 (Istituto Superiore di Sanità, 2020). The group mainly focuses on the areas of 
prevention and management of any suspected, probable or confirmed cases of COVID-19. The 
general measures highlighted by the group are related to strengthening the prevention and control of 
infections related to healthcare assistance, including by adequately training healthcare staff. The 
actions taken must ensure that there is robust management to prevent the entry of COVID-19 cases 
into the country and to manage any suspected, probable or confirmed cases that occur among 
residents in healthcare settings. This document highlights the importance of active surveillance of the 
interactions between residents in healthcare settings and staff as regards the early identification of 
cases. Facilities must be able to temporarily isolate suspected cases and, if effective isolation is 
impossible for the clinical management of the confirmed case, transfer those with confirmed cases to 
a hospital or other appropriate facility for isolation, further clinical evaluation and the necessary care, 
such as a facility dedicated to COVID-19 patients. 
Expertise to stakeholders: guidelines and recommendations 
During the COVID-19 pandemic, many new clinical and public health recommendations and 
guidelines were issued for different stakeholders, such as professionals working in drug coordination 
services, staff of treatment and harm reduction centres, and policymakers and decision-makers, as 
well as drug users themselves. This ensured that evidence-based information was available and that 
it was meeting stakeholders’ different needs. 
The NFPs have played an important role in the process of creating, drafting and revising these 
documents, either through expertise given in the working groups or by themselves producing 
guidelines or recommendations (see section on dissemination of COVID-19-related information for 
more details). 
As the EMCDDA Trendspotter briefing (2020c) on the impact of COVID-19 on drug services and help-
seeking in Europe shows, 23 European countries reported on the availability of specific guidelines for 
drug services on responding to the COVID-19 emergency in May 2020. Of these, 11 countries rapidly 
developed specific guidance addressing drug services or drug-related problems. Many countries 
13 
 
translated guidelines or briefings published by international organisations such as WHO and the 
ECDC (including the EMCDDA COVID update, which is described in detail in section on 
dissemination of COVID-19-related information). Among the countries reporting that targeted 
guidelines were available, a proportion of them reported having published national-level guidelines 
and others reported that specific guidelines had been created by non-governmental organisations. 
Table 2, in the annex, lists the national guidelines and recommendations with NFPs involvement, with 
links to documents where available. 
The Spanish NFP responded to national parliamentary requests. The NFP also provided data for 
international reports (produced by the UNODC, the EMCDDA, other countries, etc.) related to the 
situation/experience of drug users in Spain during the COVID-19 pandemic. Moreover, the Spanish 
NFP supported drug-related services by disseminating national and international recommendations 
and actively participating in the development of protocols and new guidelines for facilities for helping 
drug users. 
In Czechia, the national drug policy coordination office issued national guidelines in April 2020 and, in 
March 2020, a set of 14 formal recommendations were published for employees of addiction 
treatment and harm reduction centres, with the collaboration of the NFP. Moreover, the NFP 
collaborated in the provision of practical advice for drug users during the pandemic. Moreover, the 
Czech NFP contributed substantially to guidelines also developed by the national drug policy 
coordination office,  for addiction services for the so-called second wave of COVID-19 in autumn 
2020. These guidelines contain a set of recommendations structured according to three different 
epidemic regimens. 
Similarly, in Cyprus, the NFP participated in the process of reviewing, translating and disseminating 
guidelines for both the staff of treatment centres and drug users during the pandemic. 
In both Estonia and Latvia, the NFPs adapted available COVID-19 materials to local needs and 
translated the information available from the EMCDDA to create COVID-19 guidelines and 
recommendations for service providers, namely harm reduction and/or treatment centres. 
The Lithuanian NFP actively participated in the creation and dissemination of recommendations for 
high-risk drug users, which were created using information from the EMCDDA, WHO and the Harm 
Reduction Coalition; this information was shared with national harm reduction services. The NFP also 
disseminated recommendations to city mayors for service providers, based on the EMCDDA update 
on the implications of COVID-19 (EMCDDA, 2020a), suggesting that they keep harm reduction 
services open despite the lockdown. 
The Slovenian NFP cooperated with the NIJZ and social protection programmes in the fields of 
drugs, addiction and homelessness to create hygiene recommendations for drug service providers 
during the COVID-19 pandemic. Moreover, they were part of a working group that issued 
recommendations for working with vulnerable groups during the COVID-19 pandemic. These 
recommendations concerned broader groups of vulnerable people, such as homeless people, addicts, 
refugees, migrants, prisoners and more, and they were created in collaboration with several experts 
at the NIJZ. 
In Portugal, the NFP also coordinated a national working group that included the Intervention Division 
in Addictive Behaviours and Dependencies (DICAD) and the Social Security Institute. This group 
prepared guidelines for services working with homeless people with alcohol use disorders in shelters 
during the COVID-19 state of emergency. There were also specific recommendations issued for drug-
related treatment centres. Both recommendations were disseminated at the national level by the NFP. 
Finally, the NFP in Italy contributed to guidelines for reorganising the activities that were deferred 
owing to the COVID-19 emergency (Ministero della Salute, 2020) and guidelines for the progressive 
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reinstatement of activities that had been considered deferrable in light of the COVID-19 emergency. 
These guidelines set out all of the recommendations to be followed in the care and treatment 
pathways, and how to reinstate previously deferred activities; they were issued in partnership with the 
Superior Institute of Health. In addition, the Department for Drug Policies of the Presidency of the 
Council of Ministers and the Superior Institute of Health signed an interinstitutional agreement related 
to the prevention and control of COVID-19 infection among drug service providers. This document set 
out the framework for a project that aimed to develop guidelines for the prevention and control of 
SARS-CoV-2 infections in public and private drug services, to provide distance training to the staff of 
these services, to monitor the implementation of any guidelines updating the framework, to 
disseminate evidence among both the users and the staff of these drug services, and to provide 
training and information to public and private drug addiction services through channels other than 
documentation (Presidenza del Consiglio dei Ministri Dipartimento per le Politiche Antidroga, 2020). 
Dissemination of COVID-19-related information 
All Reitox NFPs have actively disseminated information regarding the impact of the COVID-19 health 
crisis on drug users, drug use patterns and drug services. In line with their mandate or the mandates 
of their institutions, a majority of NFPs have disseminated national and international guidelines, 
recommendations, articles, etc. 
In Czechia, the NFP disseminated, via its website, the WHO guidance for the prevention and control 
of COVID-19 in prisons (WHO, 2020a, 2020b), which was translated by a non-governmental 
organisation. The Croatian NFP disseminated the recommendations of the Croatian Psychiatric 
Community on the possible consequences for drug users (Hrvatski Liječnički Zbor, 2020) and the 
recommendations for preventing COVID-19 in the prison system (HZJZ, 2020a). The Maltese NFP 
provided guidance and assistance to prisons in setting up a system of control for COVID-19. The 
prison authorities have received support for the introduction of the system if needed. The NFP played 
an active role in sharing guidelines on telemedicine with treatment centres. The NFP supported 
centres in the use of an online portal and gave instructions for these interventions to be recorded in 
the national treatment monitoring system. These data will be further used in policy outlines on 
alternative service provision. In other countries, such as Cyprus, the NFP provided support and 
official documents to drug users for COVID-19 testing. The Lithuanian NFP prepared an overview of 
the impact of COVID-19, which will be published in an annual report. Moreover, the NFPs have set up 
websites and portals that provide general information about the COVID-19 situation. 
EMCDDA briefings and other publications 
Half of the NFPs translated, reviewed and disseminated the EMCDDA Update on the Implications of 
COVID-19 for People Who Use Drugs and Drug Service Providers (EMCDDA, 2020a). The briefing is 
available in 10 languages on the EMCDDA website (EMCDDA, 2020g). This ad hoc publication 
describes the context of the COVID-19 outbreak in the European Union and its consequences for 
drug users and drug services. Moreover, it outlines important considerations for ensuring effective 
functioning of drug services during the health crisis. The content of the update was integrated into or 
used for the development of national recommendations by the NFPs; a few NFPs also disseminated a 
printed version of this update. Table 3, in the annex, lists the NFP websites where the translation of 
this update can be found. 
As already mentioned earlier in this report, some NFPs have also translated and disseminated other 
COVID-19-related publications of the EMCDDA, such as Trendspotter briefings (EMCDDA, 2020b,c) 
and the report on the impact of COVID-19 on EU drug markets (EMCDDA and Europol, 2020), and 
are preparing or have produced national factsheets displaying the results of the Mini-EWSD. 
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The Spanish NFP has developed a communication strategy on COVID-19 to disseminate and share 
information and updates through different channels. It is based on three strategic pillars of the vision 
of the Government Delegation: (1) to be a benchmark for citizens in the matter of addictions, (2) to 
disseminate the results of the research, so they can contribute to finding solutions to social challenges 
such as the COVID-19 pandemic, and (3) to improve the website (2) and the Twitter channel 
(@PNSDgob) of the Government Delegation by publishing updated evidence-based information on 
COVID-19 and addictions (publications, recommendations of international organisations, guides and 
scientific articles). The NFP disseminates this information through different channels (its website, 
Twitter, other social networks, etc.). The NFP actively disseminates various COVID-related surveys 
(designed by the Spanish Observatory on Drugs and Addictions, by the EMCDDA, by European 
research groups, etc.) and COVID-19- and addictions-related prevention materials (Plan Nacional 
sobre Drogas, 2020a). 
 
 
Dissemination of information and provision of guidance to professionals 
The Maltese NFP has distributed information and guidance on those receiving opioid substitution 
treatment in quarantine. The NFP was approached by the contact tracing team about the difficulties of 
some patients accessing opioid substitution treatment, namely if they were in obligatory quarantine. 
The NFP sent out-patient clinics instructions on how these situations were to be dealt with. These 
patients had to contact relatives or acquaintances to pick up a week’s supply of medication, which 
was to be taken according to the instructions. This information was passed to the relevant authorities. 
Furthermore, the NFP has provided guidance to the Health Superintendent and contact tracing team 
on matters of drug users ‘trapped’ in COVID-19 confinement. The NFP provided guidance on how to 
assist a person in need and provided relevant telephone numbers and guidance on how to manage 
first contact with a drug user in a crisis (e.g. if they are feeling bad, depressed or in need of medical 
attention). The information was passed, via a key person, to the entire team, and the NFP stayed in 
contact in case further assistance was needed. 
The Danish NFP prepared various files and provided guidance and recommendations related to 
COVID-19 to professionals and drug users of consumption rooms, as well as to vulnerable groups in 
shelters and other low-threshold services. Moreover, the NFP delivered guidance on handling 
overdoses among opioid addicts, recommendations for treatment centres on opioid substitution 
treatment and take-home doses, and recommendations for cases of intoxication and withdrawal 
during the COVID-19 crisis. All information was also made available on the NFP’s website. 
In Portugal, there was an adjustment to opioid substitution treatment regulation to allow an increase 
in take-home dosages. The Portuguese NFP disseminated this information to treatment and harm 
reduction centres. It has also disseminated, on SICAD’s website and through social networks, 
information about extending the hours of the telephone helpline and information on increasing non-
face-to-face clinical activity, namely by carrying out appointments via telephone and the internet, at 
the national level. The Latvian NFP disseminated information on COVID-19-related issues to low-
threshold centres. 
 
(2) http://www.pnsd.mscbs.gob.es 
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The Irish NFP produced an evidence brief on the impact of COVID-19 in four areas: Scotland (United 
Kingdom), New South Wales (Australia), British Columbia (Canada) and New York State (United 
States). In April, the Irish Department of Health and Social Care (DOH) established a rapid 
assessment group to look at the impact of the pandemic in Ireland. As part of this rapid assessment, 
the DOH asked the Irish NFP to prepare an evidence brief examining the situation in a number of 
comparable jurisdictions. This rapid evidence brief helped the DOH put the Irish response to the 
COVID-19 crisis within an international context (Mongan et al., 2020). The findings enabled a 
comparison to be made with the situation in other countries and helped in identifying initiatives that 
could be relevant to the drugs situation in Ireland. The evidence brief included an analysis of Irish 
data from the EMCDDA’s Mini-EWSD. 
Many of the NFPs have also created websites, web pages and web services for providing information, 
guidance and support related to COVID-19 and drug use. For instance, a web-based information 
service for drug services was created in Czechia. In Finland, the dissemination of information on 
COVID-19 and people who use drugs was done through a special website and a PDF document. The 
Irish NFP compiled a special COVID-19 portal on its website, which contained details on guidelines 
and new and updated information. The Swedish NFP is involved in monitoring developments and 
analysing the consequences of the pandemic from a broad public health perspective. Dissemination 
at the national level is done continuously through the Swedish Public Health Agency’s website. The 
Portuguese NFP created a section on its website on COVID-19 for both professionals and citizens, 
namely on the SICAD web page. In Norway, information was disseminated at the national level on 
the websites of the Norwegian Centre for Addiction Research and the Directorate of Health, with a 
note included on the consequences of COVID-19 for vulnerable populations, including people who 
use drugs. The Netherlands has produced a synthesis of knowledge on the impact of COVID-19 on 
the drug situation, which presents data on (1) the effects of COVID-19 on drug use, (2) the risks of 
drug use and COVID-19, (3) the assistance available to drug users during the crisis, (4) the situation 
and best practices in harm reduction and (5) the impact of COVID-19 on drug markets. The 
information is presented on the website of the Trimbos institute (Trimbos institute, 2020). 
The Polish NFP, the National Bureau for Drug Prevention, prepared information about COVID-19 for 
treatment and harm reduction centres. In addition, this NFP has organised a series of webinars to 
present and discuss the results of the Polish NFP study about COVID-19 and new working methods 
for treatment centres and harm reduction programmes. Moreover, the Polish NFP summarised the 
COVID-19 situation in Poland at the World Drug Day event on 26 June, organised by the UNODC as 
part of the launch of the Drug Report webinar. 
Videos 
The NFP in Cyprus produced and promoted a short 
video (3) regarding the potential consequences of COVID-
19 on mental health and drug use, and mentioning the 
relevant helpline. This video demonstrates and 
encourages healthy ways of working at home and 
alternatives to the development of risky behaviours. 
The Portuguese NFP created a new prevention web page on the SICAD website (SICAD, 2020). It is 
a freely accessible web page and addresses confinement and the risks associated with addictive 
behaviour. It was created to share health information, disseminate resources and support people in 
dealing with the current situation.  
 
(3) https://www.youtube.com/watch?v=yNfqr_kySqA 
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SICAD is raising awareness of the risk of addictive behaviours worsening as 
a way for people to deal with the situation of confinement. It is intended to 
appeal to different audiences, for example to families, and it demonstrates 
different perceptions of the pandemic from different points of view. It is part 
of the universal prevention programme ‘Me and the others’, and there is an 
associated video (4). 
 
National focal points’ new activities or changes in regular service 
provision 
Several countries have initiated new activities or adapted previous activities during the COVID-19 
pandemic to support both the staff of drug services and drug users. For instance, the Croatian NFP 
created a telephone line for psychological help (HZJZ, 2020b), whereas Czechia has been providing 
a daily information service providing news related to the coronavirus situation. It is an email service 
that provides links to all services listed in the ‘Map of Aid’ (National Monitoring Centre for Drugs and 
Addiction, undated). Moreover, a telephone and email service was created to provide practical advice 
for the staff of addiction treatment and harm reduction centres during the pandemic. The support 
included providing information on personal protective equipment usage, service provision 
recommendations, etc. The weekly online support and information exchanges with members of 
umbrella associations and main service providers was organised through videoconferences. Finally, 
the Czech NFP has assisted strengthening the collaboration between different services, such as food 
providers and drug services, in Prague. 
In Cyprus, the NFP provided funding for additional services during the pandemic. It increased funding 
to reinforce new and existing services, such as a new helpline, increased coupon provision and 
increased naloxone provision to drug treatment centres without prescription. In Portugal, the NFP 
also provided additional funding to harm reduction centres, reinforced by a contribution from the 
private sector (Gulbenkian Foundation), and increased the provision of naloxone to treatment centres. 
Italy published a ministerial decree to allow electronic prescriptions of medicines containing narcotic 
or psychotropic substances. 
Impact of COVID-19 on the Reitox national focal points 
Consequences on working conditions 
In the European Union, over a third (37 %) of those currently working began to telework as a result of 
the pandemic. The largest proportions of workers who switched to working from home were found in 
the Nordic and Benelux countries (close to 60 % in Finland and above 50 % in Belgium, Denmark and 
the Netherlands, and 40 % or more in Ireland, Italy, Austria and Sweden; Eurofound, 2020). 
Many of the NFPs’ tasks can be done remotely and most of the staff of NFPs followed their national 
guidelines and switched to teleworking or alternated between their workplace and teleworking. Some 
NFPs reported greater or fewer difficulties in adapting compared with their previous experience of 
telework, but also as a result of the availability of technological means of teleworking. 
None of the NFPs had an interruption of activities. As two thirds of the NFPs are located in or closely 
linked to their ministry of health, early on, most NFPs were closely associated with COVID-19 crisis 
management at the national level, not only in terms of drug-related issues, but also as regards public 
 
(4) https://www.youtube.com/watch?v=Y8hs9VFf96M 
18 
 
health issues generally. As a consequence, few NFPs reported a shift of human resources to 
reinforce other teams involved in monitoring the evolution of the COVID-19 situation. 
In Luxembourg, there was a staff reduction of 50 % at the NFP from mid-May onwards, as additional 
support was requested by the Directorate of Health for COVID-19 epidemiological monitoring 
purposes. The NFP staff was reallocated to the COVID-19 monitoring team, which is responsible for 
trend analysis and the reporting of positive COVID-19 cases in nursing care and retirement homes for 
the elderly. As the Luxembourg NFP is located within the Department of Epidemiology and Statistics 
at the Directorate of Health, which is the executive body under the Ministry of Health, no additional 
recruitment for the NFP was undertaken as a result of this reallocation of staff. As the duration of the 
COVID-19 crisis is currently unknown, it is not yet clear when these staff will be reintegrated into the 
NFP. Therefore, since the beginning of the crisis, the sustainability of the NFP has been put at risk. 
Communication with key stakeholders has nonetheless continued and various dialogues have taken 
place to gain an understanding of their needs at this challenging time. However, the majority of the 
NFP’s other ongoing activities have been put aside, and these will be fully resumed only once the 
COVID-19 situation has further calmed. 
Other NFPs experienced changes to their working conditions, such as the Swedish NFP, which is 
located within the Swedish Public Health Agency, the main institution responsible for coordinating 
measures against COVID-19 nationally to prevent the spread of infection. Some resources were 
shifted from the NFP to monitor the impact of COVID-19 on overall public health. The Latvian NFP is 
located in the Centre for Disease Prevention and Control of Latvia, which is the main institution 
responsible for monitoring the spread of COVID-19 in the country. As the situation has become more 
and more complicated, and owing to a lack of human resources in the infection department, staff from 
other units have been moved to areas dealing with COVID-19 issues, such as working on the COVID-
19 hotline, calling people to inform them about test results, supervised social media, etc. The 
Romanian and Slovenian NFPs also experienced a reduction in staff due to COVID-19, with a 
temporary reallocation of staff to other activities to support other departments of their host institution. 
Consequences on drug-related monitoring activities 
The challenges faced by NFPs during the COVID-19 health crisis did not solely affect the working 
conditions within NFPs and the way the service was provided. In some cases, as a result of the 
reduction in NFP staff and the transfer of NFP staff to other units, there is expected to be a significant 
effect on drug-related reporting activities. Several countries reported issues and are expecting to see 
an impact on data collection in the coming year. 
In Finland, the NFP is located in the National Public Health Institute, where all COVID-19-related 
issues are prioritised over other work programmes, such as drug-related monitoring. In practice, this 
means that, for instance, other data collections are being postponed to enable the data providers to 
concentrate on collecting, recording and submitting data on COVID-19-related issues. 
In Portugal, the COVID-19 situation might affect the capacity of the NFP to collect data in 2021. 
The COVID-19 situation is affecting the Norwegian NFP’s work capacity primarily through access to 
data. Some data collections may be delayed and, on top of this, there are likely to be potential 
methodological implications, such as implications for response rates and changing patterns of 
substance use during the crisis. 
The French school survey planned for spring 2020 was postponed to November 2020, creating a 
medium-term effect on data collection. In addition, it was decided that the Lithuanian general 
population survey, which was planned for 2020 to 2021, would be postponed because of the risks of 
using a face-to-face data collection method. Moreover, in Italy, it was also decided that the general 
population survey planned for 2020 to 2021 would be postponed. 
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In Belgium, the NFP lost the possibility for data collection, for instance data on drugs or syringes, as 
some services are no longer open (needle exchange programmes, low-threshold centres, etc.). 
Laboratories are also understaffed, which will have an impact on the available data collections in the 
coming years. A nightlife survey was planned for May 2020, but was postponed until 2021. 
In Greece, the crisis will have an impact on treatment demands, as some services have been closed. 
In 2020, data are still being collected, but they will be very limited because the opioid substitution 
treatment programme, which accounts for approximately 80 % of the treatment demand indicator and 
drug-related infectious diseases data in Greece, stopped taking on new clients at the beginning of 
March because of COVID-19. 
Lessons learned 
Because of NFPs’ significant and long-running experience with data collection, systematic drug-
related monitoring and reporting activities, there has been no major disruption in their work. However, 
there are some concerns resulting from the postponing of some surveys, such as general population 
surveys and regular monitoring activities in treatment centres or in other services, and from the 
understaffing of drug services and the relocation of staff from NFPs to other departments due to the 
COVID-19 crisis. Drug user populations are vulnerable groups, and it is very important to be vigilant 
and continue to monitor the evolution of trends. The sustainability of the activities of NFPs is not really 
at stake, despite the sudden changes in priorities as described in this report. 
Several lessons have been learned from this crisis and from the challenges faced by the NFPs. First, 
NFPs’ culture of preparedness to handle risk management and their experience in crisis 
communication have played an important role over recent months. The NFPs showed an ability and 
the flexibility to shift and relocate staff to be able both to manage monitoring of the COVID-19 health 
crisis and to continue the usual monitoring of vulnerable groups and their rapidly changing drug use 
patterns. NFPs managed to adapt their working processes, such as switching to teleworking and/or 
online services. This crisis demonstrates the need to have reliable communication systems and 
procedures for business continuity. Crisis communication plans should be available for all types of 
services. 
Second, the capacity to innovate in terms of systems, communication and data collection is very 
important. In some cases, it was necessary to make changes to NFPs’ regular activities, especially by 
introducing new methods, ideas or products. For instance, it was important to implement rapid 
assessments, to adapt routine tools and to publish frequent updates of the situation regarding drug-
related matters during this health crisis. The COVID-19 crisis also helped to increase the collaboration 
at the national level with other national networks, not only with those related to illicit and licit drugs, 
but also with those related to the overall (public) health system and to law enforcement (Figure 2). 
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Figure 2 
NFPs: at the heart of the network 
 
Source: EMCDDA (2017). 
 
Third, when it comes to the dissemination and sharing of expertise, practices and experience, 
collaboration between diverse networks and stakeholders plays a key role. 
Collaboration is also one of the main functions and roles of the Reitox network, as it is the information 
interface between the EMCDDA and national-level stakeholders. The Reitox Development Framework 
defines the main priorities of the network in fulfilling its roles and functions in the future (EMCDDA, 
2018b). One of its objectives is to strengthen horizontal cooperation between NFPs and the exchange 
of best practices in monitoring the drug situation. 
Several NFPs have also collaborated with the EMCDDA and the Reitox network to share best 
practices during the COVID-19 crisis. The NFPs collaborated nationally with harm reduction networks, 
for instance through online meetings and webinars, at the national and international levels, to allow 
the flow of information and communication (back and forth). Others communicated with mayors of 
cities and involved the decision-makers, fostering collaboration between networks at the local level. 
The knowledge and experience exchange among the Reitox network has been significant during the 
crisis, with there having been rapid changes in drug use patterns and other challenges. This was an 
added value for the NFPs and their national stakeholders, as this knowledge and experience 
exchange allowed helpful information to be gathered in a very timely manner and activities at the 
national level to be strengthened and to benefit from European experience and added value. 
Finally, one of the key roles of each NFP is to act as a coordinator of the national drugs information 
system, at all levels (local, regional, national and international), and in times of crisis this role is 
essential. NFPs have initiated or participated in various meetings with national stakeholders in the 
context of the public health emergency and owing to the need for data. This was key to maintaining a 
coherent monitoring approach, limiting the profusion of overlapping national or local surveys and 
giving appropriate and timely responses. 
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NFPs play a key role in leadership and coordination. Working together with stakeholders in the 
creation and evaluation of reports and immediately responding to current needs are vital in times of 
crisis. The NFPs provided timely overviews of the situation and demonstrated their capacity to adapt 
to the crisis and to be flexible. It was an opportunity for the network to demonstrate its ability to cope 
with new and challenging situations and to produce quick and useful responses. In the future, it is 
highly likely that virtual communication tools, such as online meetings and webinars, will continue to 
be used as powerful tools of communication and for connecting different stakeholders, and to improve 
service provision to drug users. 
The NFPs learned that they can achieve a lot, sometimes with simplified procedures, even under 
extreme time pressure and with scarce human resources. Finally, new practices were adopted that 
could improve the availability of drug services to those in need, and this will hopefully remain true in 
the long run. 
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Annex 
Table 1. National surveys and ad hoc studies performed by NFPs during the COVID-19 health crisis 
Country Study Description Status Output 
Belgium A national web survey to monitor the impact of the 
COVID-19 crisis among drug users by evaluating 
both drug-related and health-related issues 
relevant to health professionals, prevention 
services and decision-makers 
A study to support the work of health 
professionals, prevention services and decision-
makers during the pandemic and determine its 
long- and medium-term consequences 
Ongoing The results of the first two 
waves are published in 
Sciensano (2020a, 2020b) 
Belgium Rapid assessment of the impact of COVID-19 in 
treatment and harm reduction services, 27-31 
March 2020 
A study to assess the first impacts of the 
government’s measures related to the COVID-19 
crisis (the so-called lockdown of 13 March 2020), 
namely the impacts within 15 days after the entry 
into force of these measures 
Finished Unpublished 
Czechia Active monitoring of the changes in treatment and 
harm reduction provision and the issuing of three 
rapid assessment reports 
A rapid assessment report for national 
stakeholders on the impact of COVID-19 and the 
adaptations and responses to the crisis 
Finished Rapid assessment reports 
(National Monitoring Centre 
for Drugs and Addiction, 
2020a, 2020b) 
Czechia Serobehavioural study entitled ADI-COVID-19 The study aimed to determine the seroprevalence 
of coronavirus (SARS-CoV-2) infection and 
identify suspected cases of infection among 
clients and staff of addiction programmes. It 
included rapid testing and questionnaires among 
clients and workers of drug services 
Finished The study is available at 
National Monitoring Centre 
for Drugs and Addiction 
(2020c) 
Czechia National survey on substance use An online survey conducted every four years that 
was adapted to the COVID-19 situation. A special 
module was inserted on changes in substance use 
and addictive behaviours, such as gaming, 
gambling and social media use, during the 
COVID-19 health emergency 
Ongoing  
Czechia Monitoring of the interventions carried out by non-
governmental organisations 
An online facility survey with COVID-19-related 
questions added and interim reports of the 
projects 
Ongoing  
Estonia Monitoring effects of COVID-19 in harm reduction 
services, treatment centres and other services 
Data collection Ongoing  
Greece Drug professionals on their experience of the 
COVID-19 health emergency 
The NFP supported the national coordinator in the 
creation and dissemination of a questionnaire 
Ongoing  
Spain Drug use and other addictions during COVID-19 An analysis of the changes registered based on 
the routine information system (including Key 
Finished The report is available at 
Plan Nacional sobre Drogas  
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Country Study Description Status Output 
Indicators) and also results of questionnaires and 
online surveys conducted ad hoc. The report 
contains information related to illicit drugs, alcohol, 
tobacco and behavioural addictions 
DGPNSD OEDA (2020)  
Spain Mini-EWSD: impact of COVID-19 on illegal drug 
use in Spain 
An analysis of the Mini-EWSD (European Web 
Survey on Drugs) data in Spain 
Finished DGPNSD OEDA (2020) 
France Compilation of a survey report with data on the 
effects of COVID-19 
 Finished OFDT (2020; in French) 
Italy Evaluation of the changes in drug use among 
students during the lockdown 
Online survey among a sample of Italian students, 
conducted by the Institute of Clinical Physiology of 
the National Research Council 
Ongoing   
Lithuania Monitoring of alcohol and drug-related non-fatal 
overdoses 
Comparing 2019 data with the situation during the 
quarantine period 
Finished NTAKD (2020a) 
Luxembourg Evaluation among low-threshold services to 
assess the impact of COVID-19 and the related 
measures among high-risk drug use clients at 
harm reduction and supervised drug consumption 
facilities at the national level 
Developed with the collaboration of the national 
drug coordinator and directors of services. Data 
collected by a written questionnaire 
Ongoing  
Luxembourg Flash-COVID No 2: L’impact de la crise COVID-19 
sur les usagers de drogues et les services 
d’encadrement specialises 
Flash COVID-19: Impact of the COVID-19 public 
health sanitary crisis on drug users and drug 
service providers 
Collaboration between the NFP with the national 
statistics agency (STATEC Luxembourg) and the 
national drug coordinator 
Finished Ministère de la Santé et al. 
(2020) 
Luxembourg Survey in prison Interviews carried out in August 2020 Ongoing  
Hungary  Drug use and access to harm reduction and 
treatment services during the COVID-19 crisis 
National survey among service providers by the 
NFP 
Finished Publication in preparation 
Hungary HIV/HCV/COVID-19 biobehavioural survey among 
high-risk drug users (including people who inject 
drugs) in Budapest 
Survey by the NFP and a Budapest-based non-
governmental organisation 
Ongoing   
Hungary Changes in the drug market and seizures of drugs 
by authorities, emergency care and acute 
intoxications and forensic medicine 
Interviews Finished  
Hungary National prison facility survey with a specific 
module on COVID-19  
Survey by the Prison Service Headquarters and 
the NFP 
Ongoing  
Netherlands Mini cannabis and COVID-19 survey Four in ten cannabis users increased their use 
due to boredom but also stress and loneliness 
Finished Vercoulen et al. (2020) 
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Country Study Description Status Output 
Netherlands National Big Nightlife Survey 2020 adapted to 
COVID-19, covering the first phase of the 
lockdown; a second survey covered the period 
from June to September 
A new question has been included in the survey, 
and a follow-up and new round is planned in 
September/October 
Until May 2020  The results of the first round 
are available at Van 
Miltenburg et al. (2020) 
Netherlands Inventory of the impact of COVID-19 on harm 
reduction services 
A study (three inventories) conducted and put 
together with Mainline and MDHG; the results 
were discussed at the Ministry of Health and 
distributed to stakeholders 
Finished; fourth 
round will be held in 
October 
Trimbos institute (undated) 
Poland National study (April-May) entitled ‘The impact of 
COVID-19 on drug services, drug users and drug 
market in Poland’ 
Four publications in Polish journals to present the 
findings: (1) Świat Problemów, (2) Serwis 
informacyjny UZALEŻNIENIA, (3) Remedium and 
(4) Terapia Uzależnienia i Współuzależnienia 
National-level questionnaire among treatment 
centres, harm reduction programmes, regional 
experts on drugs, non-governmental organisations 
and the police 
Finished Malczewski et al. (2020; in 
English) 
(1) 
http://www.swiatproblemow.p
l/ 
(2) https://siu.praesterno.pl/ 
(3) http://www.remedium-
psychologia.pl/ 
(4) http://www.tuiw.pl/ 
Poland Health conditions of people receiving injections in 
the field of infectious diseases — seroprevalence 
study on HIV, HCV, SARS-CoV-2 and the bacteria 
Treponema pallidum 
In collaboration with the national drug-related 
infectious diseases expert 
Ongoing  
Portugal  Study on the impact of COVID-19 on addictive 
behaviours 
Three online surveys: (1) alcohol and medication 
use, (2) internet and video games and (3) 
cannabis use 
Finished The report is available at 
SICAD (2020) 
Slovenia The impact of the COVID-19 pandemic on 
treatment and provision services for drug users 
and on the drug market in Slovenia 
Rapid assessment report for national and regional 
stakeholders on the impact of COVID-19 
Finished Drev (2020) 
Finland Survey among drug services about changes in 
services provision and demand 
Qualitative survey repeated approximately every 5 
weeks (excl. July) since the beginning of the 
epidemic. Data is collected for the Ministry of 
Social Affairs and Health which is responsible for 
service monitoring during the crisis. 
Ongoing Results are available at 
Finnish Institute for Health 
and Welfare (2020a) 
Cyprus Additional wastewater analysis Two collections during and after the lockdown Finished  
Slovakia Additional wastewater analysis Collections focused on methamphetamine, 
fentanyl, ketamine, amphetamine, cocaine, 
benzoylecgonine, MDMA, THC-COOH, tramadol, 
methadone, mephedrone and heroin and on the 
occurrence of the new coronavirus (SARS-CoV-2) 
Ongoing  
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Country Study Description Status Output 
Greece COVID-19 case tracking With the use of data from agencies, the NFP is 
monitoring the number of users infected by or 
deceased as a result of COVID-19 
Ongoing  
Italy COVID-19 case tracking Working group on infection prevention and control 
of COVID-19, mainly prevention and preparation 
of the management of any suspected, probable 
and confirmed cases 
Ongoing  
Luxembourg COVID-19 case tracking Detecting infections of COVID-19 among drug-
related death cases, in collaboration with the 
National Laboratory on Health 
Ongoing  
 
 
Table 2. NFPs that contributed to the creation of the national recommendations and guidelines 
Country Guidelines and recommendations Description Output 
Czechia Fourteen formal recommendations for employees of addiction 
treatment and harm reduction centres, plus comprehensive 
guidelines for the second wave of COVID-19 in autumn 
Issued by the Drug policy coordination office (NFP is part 
of it); collaboration on the provision of practical advice for 
drug users 
National Monitoring 
Centre for Drugs and 
Addiction (2020d) 
Denmark Guideline on the medical treatment of acute drug poisonings 
with opioids 
Guidelines for acute withdrawal and poisoning cases due 
to expected changes in the illegal drug scene 
Sundhedsstyrelson 
(2020a) 
Denmark Guideline on the treatment of cocaine abuse and abuse of other 
psychostimulants 
Guidelines concern the treatment of withdrawal symptoms 
related to the use of stimulants and benzodiazepines 
Sundhedsstyrelson 
(2020b, 2020c) 
Denmark Information for employees and volunteers in drug consumption 
rooms 
Covid-19 management guidelines Sundhedsstyrelson 
(2020d) 
 Guideline for substitutions treatment centres Separate guidelines for Danish drug and alcohol treatment 
centres regarding the management of COVID-19 
Sundhedsstyrelson 
(2020e) 
Estonia  COVID-19 guidelines and recommendations for service 
providers, and harm reduction and treatment centres 
The available materials were adapted to local needs, and a 
translation was provided of the EMCDDA information 
https://www.narko.ee/ 
Spain Guidelines and recommendations: guidelines and 
recommendations related to COVID-19 and drug users 
 
Include main documents at international, national and 
regional (Comunidades Autonomas) level in the context of 
drug use during COVID-19 
Plan Nacional sobre 
Drogas (2020) 
Italy Guidelines for reorganising the activities that were deferred 
owing to the COVID-19 emergency 
The NFP contributed to these revised guidelines Ministero della Salute 
(2020) 
Italy  Guidelines for the progressive reinstatement of activities that had 
been considered deferrable in the light of the COVID-19 
emergency 
Issued in partnership with the Instituto Superiore di Sanita  
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Country Guidelines and recommendations Description Output 
Cyprus Guidelines for (1) the staff of treatment centres and (2) drug 
users during the pandemic 
The NFP participated in the process of reviewing, 
translating and disseminating the guidelines 
Cyprus National 
Addictions Authority 
(2020a, 2020b) 
Lithuania Recommendations for high-risk drug users Created with materials from the EMCDDA, WHO and the 
Harm Reduction Coalition 
NTAKD (2020b) 
Lithuania Recommendations for service providers Created using EMCDDA information on social services 
and drug treatment providers 
NTAKD (2020c) 
Malta Guidelines for treatment centres on telemedicine The NFP played an active role in issuing the guidelines  
Portugal Guidelines for interventions related to homeless people with 
alcohol use disorders placed in shelters during the COVID-19 
state of emergency 
The NFP produced these guidelines together with SICAD 
and national working groups, including DICAD 
República Portuguesa 
Saūde et al. (2020a) 
Portugal Recommendations for the care of users in therapeutic 
communities 
Issued by the NFP República Portuguesa 
Saūde et al. (2020b) 
Slovenia Hygiene recommendations for drug service providers during 
COVID-19 epidemics 
These recommendations were produced with the 
cooperation of the NIJZ and social protection programmes 
in the field of drugs, addiction and homelessness 
NIJZ (2020a) 
Slovenia Recommendations for work with vulnerable groups during the 
COVID-19 pandemic 
The NFP was part of the working group NIJZ (2020b) 
Finland Information on COVID-19 and advices to people who use drugs Compilation of resources Finnish Institute for Health 
and Welfare (2020b) 
 
Table 3. Links to national websites providing a translated version of the EMCDDA update on the implications of COVID-19 for people who use 
drugs and drug service providers 
Country EMCDDA briefing 
Bulgaria http://nfp-drugs.bg/bg/?&itype=168&info=2834 
Czechia https://www.drogy-info.cz/publikace/zaostreno-na-drogy/2020-zaostreno/s1-20-dopady-onemocneni-covid-19-na-uzivatele-drog-a-poskytovatele-
adiktologickych-sluzeb 
 
Germany https://www.dbdd.de/publikationen/publikationen-der-emcdda 
 
Spain https://pnsd.sanidad.gob.es/noticiasEventos/actualidad/2020_Coronavirus/home.htm 
France  https://www.ofdt.fr/europe-et-international/actualites-europeennes 
 
Croatia https://www.hzjz.hr/aktualnosti/novosti-emcdda-a-o-implikacijama-virusa-covid-19-za-osobe-koji-koriste-drogu-i-pruzatelje-usluga-za-suzbijanje-droga/ 
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Country EMCDDA briefing 
Latvia http://ntakd.lrv.lt/uploads/ntakd/documents/files/Rekomendacijos%20paslaug%C5%B3%2C%20narkotikus%20vartojantiems%20asmenims%2C%20teik%C
4%97jams.pdf 
 
Lithuania https://ntakd.lrv.lt/lt/naujienos/covid-19-poveikis-narkotiku-vartojimo-iprociams-europos-salyse; https://ntakd.lrv.lt/lt/naujienos/covid-19-poveikis-su-
narkotikais-susijusiu-paslaugu-teikimui-europoje; https://ntakd.lrv.lt/lt/naujienos/covid-19-kanapes-darknet-internetas-prekyba 
 
Hungary http://drogfokuszpont.hu/emcdda-osszeallitas-a-koronavirus-jarvany-droghasznalokat-es-kabitoszerugyi-szolgaltatokat-erinto-hatasairol/ 
Netherlands https://www.trimbos.nl/kennis/corona/drugs-en-corona 
 
Poland https://cinn.gov.pl/portal?id=1623559; https://siu.praesterno.pl/artykul/678 
Portugal http://www.sicad.pt/BK/COVID19/Lists/profissionais/Attachments/12/EMCDDA%20Covid-19%20update_PT.pdf 
Romania http://ana.gov.ro/recomandari-europene-privind-implicatiile-pandemiei-covid-19-in-randul-persoanelor-consumatoare-de-droguri/ 
Slovenia https://nijz.si/sites/www.nijz.si/files/publikacije-datoteke/emcdda_prevod_koncna_230420.pdf 
Slovakia  https://www.infodrogy.sk/novinka/4580 
Finland https://www.julkari.fi/bitstream/handle/10024/139552/Koronavirus%20_COVID_19_ja_p%c3%a4ihteet.pdf?sequence=5&isAllowed=y 
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